Most VC playbooks assume you have monthly revenue charts that go up and to the right. Deeptech startups rarely do. If you are building in semiconductors, synthetic biology, advanced materials, or defence-adjacent hardware, your most important breakthroughs happen in a lab, not a spreadsheet. That creates a specific fundraising problem: how do you convince investors to write a cheque when the thing you are building does not yet exist at commercial scale? This guide addresses that question directly, with frameworks and tactics built for Indian deeptech founders navigating a market that is still figuring out how to fund long R&D cycles.
Why Standard VC Metrics Break Down for Deeptech Founders
A typical early-stage VC in India will ask for MoM revenue growth, CAC, LTM ARR, or at minimum a pilot with a paying customer. These are reasonable filters for SaaS or consumer businesses. They are nearly useless for a founder building a novel battery chemistry or a photonics-based diagnostic device. The product may not be ready for a pilot for another 18 months. The customer cannot pay for something that is not certified or manufactured yet. And the team is composed of PhDs who have never pitched a VC before.
This mismatch is not a failure of the founder. It is a category mismatch. The problem is that most generalist funds in Bengaluru, Mumbai, and Delhi are structured around 7 to 10 year horizons with return expectations that require portfolio companies to show commercial inflection within 3 to 4 years of investment. Deeptech companies often cannot meet that timeline. Recognising this early saves you from wasting months pitching to the wrong rooms.
Building a Milestone Map That Replaces Traction as Proof
If you cannot show revenue traction, you need to show something equally concrete: a milestone map that proves technical de-risking over time. This is not a product roadmap. It is a structured sequence of verifiable outcomes that reduce the probability of failure at each stage.
Think in three layers: technical milestones, regulatory or validation milestones, and commercial milestones. Each layer has a different audience. Technical milestones (proof of concept, prototype performance, IP filing) speak to the scientific risk. Validation milestones (DSIR recognition, NABL-certified test results, tie-up with a national lab or IIT) speak to credibility. Commercial milestones (letter of intent from a PSU, a non-dilutive contract, an MOU with a defence integrator) speak to eventual monetisation.
- Define 4 to 6 milestones across an 18 to 24 month window with specific, measurable outcomes attached to each
- Assign a capital requirement to each milestone so investors can see what their cheque actually unlocks
- Link each milestone to a risk reduction narrative: before this milestone, the risk is X; after it, the risk drops to Y
- Where possible, get third-party validation — IIT lab reports, CSIR test data, or industry partner sign-offs
- Show what the next funding round becomes possible once milestones are hit
This milestone map becomes your substitute for a traction slide. It tells a sophisticated investor: here is the journey, here is how you can track us, and here is what reduces your risk as we progress.
Stacking Grants and Equity: BIRAC, iHub, DST, and Beyond
One of the most underused strategies for Indian deeptech startups is building a non-dilutive capital stack before approaching equity investors. India has a genuine grant ecosystem for deeptech. BIRAC (Biotechnology Industry Research Assistance Council) funds life sciences and biotech startups through programs like BIG and SPARSH. DST (Department of Science and Technology) runs the NIDHI program and its PRAYAS grants for early-stage hardware and deep science. iHub foundations set up under NM-ICPS at IITs across the country provide both grants and structured incubation for AI, robotics, and cyber-physical systems. SIDBI's Fund of Funds has deeptech-aware downstream vehicles. ISRO's IN-SPACe and DRDO's TUSHAR scheme open doors specifically for spacetech and defence technology companies.
The strategic value of grants is not just capital. It is signal. A BIRAC BIG grant of 50 lakhs tells an equity investor that a government body with technical reviewers has already validated your science. It de-risks the early technical bet. Stacking a 30 to 75 lakh grant with a 1 to 2 crore angel round from a deeptech-aware investor lets you reach a significantly more fundable milestone before you need to go to a seed VC.
Treat grants as the first tranche of your capital plan, not as an alternative to equity. Build the application process into your 12-month roadmap. Many deeptech founders apply too late or skip grants entirely because the process seems slow. The timelines are long, but the capital is patient and non-dilutive.
How to Frame Long R&D Cycles Without Losing the Room
The moment a VC hears "we need 3 more years of R&D before launch," they start calculating exit timelines and get uncomfortable. Your job is to reframe the narrative before that calculation happens. There are two techniques that work consistently.
First, anchor to analogous exits. Point to global deeptech companies in your category that had long R&D cycles but created significant returns — without making the claim that you will replicate them. Use them to establish that the category has precedent. In the Indian context, reference iGate, SigTuple, Agnikul, or ePropelled for sector-specific credibility. Second, compress perceived risk by showing what you have already solved. A VC's fear about long R&D cycles is not really about time — it is about the probability that you will fail to crack the core technical problem. If you have already solved the hardest part, say so explicitly and show the evidence. The remaining work is engineering, not discovery.
Also, be honest about what you do not know. Deeptech investors who have been burned before are skilled at detecting founders who oversimplify remaining risks. Acknowledging the hard problems builds more trust than papering over them.
Finding the Right Deeptech-Friendly Investors in India
Not all early-stage capital in India is built for deeptech. Some funds are. Speciale Invest, Mela Ventures, and 3one4 Capital have publicly backed deeptech and hard science companies. Elevate Capital and Artha Venture Fund have made hardware and frontier tech bets. On the corporate venture side, Tata Capital, Mahindra's M&M Fund, and L&T's investment arms look at industrial deeptech. For defence and space, iDEX (Innovations for Defence Excellence) provides non-dilutive contracts up to 1.5 crore that function as revenue for early validation.
When you are mapping your investor list, check how to find the right VC in India for a systematic method of qualifying investors by thesis. Deeptech requires you to go one layer deeper: look at the partner's academic or industrial background, the fund's LP base (patient capital or quick-cycle?), and the median time from investment to follow-on in their portfolio.
Structuring Your Raise: Tranches, Triggers, and Investor Protections
Milestone-based tranching is a practical tool for deeptech raises that benefits both sides. Instead of raising a single round upfront, you agree with investors on a total commitment that is disbursed in tranches, each triggered by hitting a defined milestone. This reduces investor risk and forces the founder to stay accountable to stated goals.
- Tranche 1: Released at close — covers first 6 months of operations and milestone 1 targets
- Tranche 2: Released on hitting a defined technical or validation milestone — typically 9 to 12 months in
- Tranche 3: Released on a commercial validation event — LOI, pilot revenue, or IP grant
- Include a longstop clause so founders are not held hostage if milestone timelines slip due to factors outside their control
- Ensure anti-dilution provisions and information rights are clearly specified for all tranches, not just the first
Most early deeptech rounds in India are structured as convertible notes or SAFEs at this stage because valuation is genuinely hard to defend without revenue. If you are raising on a priced equity round, be conservative on valuation — an inflated early valuation in deeptech creates a down round risk when you still have two years of R&D ahead of you.
Common Mistakes Deeptech Founders Make When Pitching Early
- Leading with the technology instead of the problem: investors fund solutions to large problems, not interesting science for its own sake
- Underestimating regulatory timelines: if your product requires BIS certification, CDSCO approval, or defence clearance, build that into your financial model explicitly
- Not having a monetisation hypothesis: "we will figure out the business model after we build the product" is not acceptable, even in deeptech
- Pitching to generalist VCs without filtering by thesis first — read about what a VC investment thesis means before building your target list
- Ignoring team composition signals: a team of only scientists without a commercially-oriented co-founder raises questions about execution credibility
- Failing to quantify the TAM in Indian market terms — global TAMs mean little to a Bengaluru-based fund with a domestic mandate
Deeptech fundraising in India is genuinely harder than raising for a SaaS product, but it is not impossible. The founders who succeed are the ones who treat the fundraise itself as a technical problem: they understand the constraints of the system they are operating in, they find the right instruments for each stage, and they communicate progress in a language that reduces perceived risk without overpromising. Start by building your milestone map this week. Get your first grant application in motion. And then approach only the investors whose track records show they have sat with a company through a long R&D cycle before.
